Corbus Pharmaceuticals Holdings, Inc. - Common Stock (CRBP)

CUSIP: 21833P301

Q2 2026 13F Holders as of 30 Jun 2026

Security type / class
Equity / Common Stock
Total 13F shares
29,755
Total 13F value
$279,097
Holder snapshot 6 signals
Share change
-79,121
SEC-reported price per share
$9.38
Number of holders
15
Value change
-$743,231
Number of buys
4
Number of sells
5
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
18,532,780

Security key

21833P301

Report period

Q2 2026

Institutions

15

Top holders

10

CRBP full security history Ownership snapshot Full 13F holder table Previous quarter: Q1 2026 Corbus Pharmaceuticals Holdings, Inc. SEC filings Corbus Pharmaceuticals Holdings, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Cormorant Asset Managemen...
Disclosed value leader
Cormorant Asset Managemen...
Comparable rows
15/15
Latest evidence
30 Jun 2026
3/4/5 13D/G 13F Lead comparable stake: 13% 13D/G row: Cormorant Asset Management, LP Showing 1-6 of 15 holder rows.

Quick read

Cormorant Asset Management, LP leads the comparable SEC ownership view at 13%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Cormorant Asset Management, LP's linked filing trail.
Comparable ownership Top 5
Cormorant Asset Management, LP 13%
Aberdeen Group plc 7.5%
ORBIMED ADVISORS LLC 5.9%
BlackRock, Inc. 5.9%
CITADEL ADVISORS LLC 5.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Cormorant Asset Management, LP
3/4/5 13D/G 13F
10%+ Owner · Company
3/4/5 13D/G 13F
13%
from 13D/G
$26,863,987
2,344,971 shares
 -$344,012 11 Dec 2025
Aberdeen Group plc
13F 13D/G
Company
13F 13D/G
7.5%
from 13D/G
$12,411,233
1,321,750 shares
 — 31 Mar 2026
ORBIMED ADVISORS LLC
13F 13D/G
Company · OrbiMed Capital LLC
13F 13D/G
5.9%
from 13D/G
$16,313,125
1,737,287 shares
 — 31 Mar 2026
BlackRock, Inc.
13D/G 13F
Company
13D/G 13F
5.9%
$10,256,411
1,093,434 shares
 +$6,950,814 30 Jun 2026
CITADEL ADVISORS LLC
13D/G 13F
Kenneth Griffin · Company
13D/G 13F
5.3%
$12,405,011
980,610 shares
 $0 04 Nov 2025
VANGUARD GROUP INC
13D/G
The Vanguard Group
13D/G
4.9%
$4,136,516
599,495 shares
 $0 30 Jun 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
15
Shares
29,755
Rows available
15
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
107
Q2 2026 holders
15
Holder diff
-92
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .